New ALS Treatment Research to Debut
Upcoming research will provide patients with new data on progression-free survival and respiratory monitoring.
Updated on Oct. 26, 2026 in Stroke
Live Poll
Do you trust pharmaceutical companies to accurately report the risks and benefits of their new treatments?
Shionogi Inc. is scheduled to present three research posters at the 2026 Annual Network of Excellence for Amyotrophic Lateral Sclerosis (NEALS) Meeting, occurring October 27-30, 2026, in Clearwater, Florida. These presentations will detail new insights into progression-free survival and respiratory monitoring for patients with amyotrophic lateral sclerosis (ALS).
Why it matters
Understanding how treatments like RADICAVA ORS correlate with functional outcomes helps patients and their care teams refine long-term management strategies. These findings aim to clarify how specific monitoring technologies might identify those at risk of faster disease progression.
Manufacturer data shows over 22,800 people have been treated with RADICAVA products across 3.0 million days of therapy. The upcoming posters will evaluate treatment associations with progression-free survival, though definitive clinical trial outcomes remain ongoing.
The players
Shionogi Inc.
A pharmaceutical company headquartered in Florham Park, New Jersey, that researches and develops treatments for infectious diseases and neurological disorders.
NEALS
The Network of Excellence for Amyotrophic Lateral Sclerosis, an international research organization dedicated to accelerating ALS drug development.
The details
The research focuses on the clinical profile of RADICAVA ORS, which received FDA approval in 2022 and subsequent orphan drug status in 2024. Investigators are analyzing how the medication influences functional decline and using remote respiratory monitoring to better track patient stability. This research seeks to provide more precise data on how to intervene earlier when markers of rapid disease progression appear.
Timeline
May 12, 2022: FDA approval of RADICAVA ORS.
2024: FDA grants Orphan Drug Exclusivity.
October 27-30, 2026: 2026 Annual NEALS Meeting takes place.
Health Landscape
The study of ALS progression sits within the framework of the FDA Orphan Drug Act exclusivity provisions, which encourage development for rare conditions. Ongoing research like this is essential to refine standard care protocols beyond initial regulatory approval.
Patients currently managing ALS and utilizing RADICAVA ORS should discuss the role of respiratory monitoring with their neurology care team. This is a topic worth raising during your next scheduled clinical evaluation to determine if new monitoring practices are appropriate for your care plan.
The takeaway
Research continues to evolve regarding how to better track and slow the functional impact of ALS. Patients are encouraged to maintain a regular dialogue with their physician about emerging monitoring tools and potential shifts in treatment efficacy.
Further reading
For more on evolving care strategies, explore our comprehensive coverage in Stroke.
More information
Review the Full prescribing information for details on safety and usage.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical companies to accurately report the risks and benefits of their new treatments?
